Comparative Pharmacology
Head-to-head clinical analysis: CLINIMIX E 5 20 SULFITE FREE W ELECT IN 20 DEXTROSE W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 2 75 IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CLINIMIX E 5 20 SULFITE FREE W ELECT IN 20 DEXTROSE W CALCIUM IN PLASTIC CONTAINER versus TRAVASOL 2 75 IN DEXTROSE 5 IN PLASTIC CONTAINER.
CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER vs TRAVASOL 2.75% IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Parenteral nutrition providing essential amino acids, electrolytes, and dextrose for caloric support and protein synthesis.
Amino acids provide substrates for protein synthesis and energy metabolism; dextrose provides caloric support.
Intravenous. Adult: 2 L/day (providing 100 g protein and 400 g dextrose) or as per metabolic needs. Rate: 100 mL/hr initially, adjusted based on tolerance and glucose monitoring.
Intravenous infusion. Typical adult dose: 500 mL to 1000 mL per day administered at a rate not exceeding 5 mL/kg/hour, based on protein and electrolyte requirements.
None Documented
None Documented
Amino acids: 0.5-2 hours (rapid clearance dependent on metabolic demand). Glucose: ~2-4 hours in euglycemic states. No single terminal half-life due to mixture.
Not applicable; components are endogenous substances with rapid metabolic turnover. Exogenous amino acids have half-lives of minutes to hours, dextrose ~1-2 hours.
Components are primarily metabolized; nitrogen waste excreted renally as urea (85-90%), with minimal biliary/fecal elimination (<5%). Electrolytes and dextrose are fully metabolized or excreted renally.
Renal: 100% of infused amino acids and dextrose are metabolized or excreted; no intact drug excretion. Biliary/fecal: negligible.
Category C
Category C
Parenteral Nutrition Solution
Parenteral Nutrition Solution